2013
The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 63: 480-484. PMID: 23599011, DOI: 10.1097/qai.0b013e3182961d31.Peer-Reviewed Original ResearchConceptsEVG/COBIBuprenorphine/naloxoneBaseline valuesBuprenorphine/naloxone treatmentEffect of elvitegravirElvitegravir/cobicistatOpioid-dependence therapiesHIV-seronegative subjectsNorbuprenorphine levelsOpioid pharmacodynamicsOpioid withdrawalNaloxone treatmentPharmacodynamic interactionsBuprenorphine/Historical controlsPharmacodynamic studiesAUCtauCobicistatNaloxoneCmaxElvitegravirTherapySubjectsCOBISteady-state evaluationPharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients
2011
Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients
McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug And Alcohol Dependence 2011, 118: 326-334. PMID: 21596492, PMCID: PMC3272858, DOI: 10.1016/j.drugalcdep.2011.04.013.Peer-Reviewed Original ResearchConceptsBuprenorphine plasma concentrationsWithdrawal symptomsOpiate withdrawalPlasma concentrationsBuprenorphine-maintained patientsBuprenorphine-maintained subjectsDays of rifampinOpioid partial agonistBuprenorphine/naloxoneFirst-line treatmentOpiate withdrawal symptomsSignificant adverse eventsActive metabolite concentrationsOpioid-dependent individualsPlasma buprenorphine concentrationsBuprenorphine pharmacokineticsStable dosesAdverse eventsBuprenorphine doseBuprenorphine therapyAntituberculosis medicationPharmacodynamic interactionsRifampin administrationOpioid dependenceLine treatmentTipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone
Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH. Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone. The American Journal Of Drug And Alcohol Abuse 2011, 37: 224-228. PMID: 21438849, DOI: 10.3109/00952990.2011.568081.Peer-Reviewed Original ResearchConceptsTPV/rSteady-state pharmacokinetic evaluationGlucuronide metabolitesBUP/naloxoneHIV-negative subjectsHIV-seronegative subjectsBuprenorphine/naloxoneSteady-state pharmacokineticsCytochrome P450 3A4Ritonavir effectsPharmacodynamic consequencesPharmacokinetic evaluationBuprenorphineNorBUPCombined inhibitionNaloxoneCurve AUCP450 3A4AUCSignificant increasePharmacokineticsTipranavirPrevious reportsSubjectsMetabolitesIntegration of Buprenorphine for Substance-Abuse Treatment by HIV Care Providers
Friedland G, Vlahov D. Integration of Buprenorphine for Substance-Abuse Treatment by HIV Care Providers. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s1-s2. PMID: 21317588, DOI: 10.1097/qai.0b013e31820bc9ba.Peer-Reviewed Original Research
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLX
2006
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin DA, Friedland GH, Gourevitch MN. Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases 2006, 43: s173-s177. PMID: 17109303, DOI: 10.1086/508180.BooksConceptsOpioid agonist treatmentOpioid dependenceAgonist treatmentHuman immunodeficiency virus (HIV) transmissionBuprenorphine/naloxone combinationNeurobiological basisOpioid withdrawalBuprenorphine treatmentHIV infectionDecreased riskNaloxone combinationOpioid receptorsGeneral physiciansMedical disordersNew treatmentsMethadoneVirus transmissionBuprenorphineTreatmentMedicationsPatientsChronicInfectionIntracellular processesPhysiciansInteractions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006, 43: s224-s234. PMID: 17109309, DOI: 10.1086/508187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesArea Under CurveBenzoxazinesBuprenorphineCase-Control StudiesCohort StudiesCyclopropanesDelavirdineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHumansMaleNarcotic AntagonistsOpioid-Related DisordersOxazinesProbabilityPrognosisReference ValuesReverse Transcriptase InhibitorsRisk AssessmentStatistics, NonparametricTreatment OutcomeConceptsNonnucleoside reverse transcriptase inhibitor efavirenzReverse transcriptase inhibitor efavirenzInhibitor efavirenzPharmacokinetics of buprenorphineOpiate withdrawal symptomsAdjustment of dosesEffects of buprenorphineHuman immunodeficiency virusConcentration-time curveOpioid-dependent participantsHealthy control participantsAntiretroviral administrationAdverse eventsAgonist medicationsHIV diseaseNegative volunteersStandard dosesOpioid dependenceImmunodeficiency virusBuprenorphine concentrationsWithdrawal symptomsAntiretroviral pharmacokineticsDrug interactionsOpiate dependenceBuprenorphineInteractions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. Clinical Infectious Diseases 2006, 43: s235-s246. PMID: 17109310, DOI: 10.1086/508188.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCase-Control StudiesCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV Protease InhibitorsHIV SeronegativityHumansLopinavirMaleNarcotic AntagonistsNelfinavirOpioid-Related DisordersProbabilityPyrimidinonesReference ValuesRisk AssessmentRitonavirConceptsLPV/rLopinavir/ritonavirProtease inhibitor nelfinavirOpioid dependenceAdministration of ritonavirOpioid partial agonistAdjustment of dosesHuman immunodeficiency virusConcentration-time curveHealthy control participantsPI administrationPI pharmacokineticsHIV diseaseNegative volunteersImmunodeficiency virusOpiate withdrawalDrug interactionsBuprenorphineRitonavirPartial agonistNelfinavirControl participantsPharmacokinetic studyAdministrationSignificant increase
2001
Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition
McCance‐Katz E, Rainey P, Friedland G, Kosten T, Jatlow P. Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition. American Journal On Addictions 2001, 10: 296-307. PMID: 11783744, DOI: 10.1111/j.1521-0391.2001.tb00519.x.Peer-Reviewed Original ResearchConceptsOpioid-dependence pharmacotherapyHuman immunodeficiency virusZDV toxicityActive antiretroviral therapyInjection drug usersTime-concentration curveZDV pharmacokineticsZidovudine dispositionAntiretroviral therapyOpioid pharmacotherapyDose adjustmentOpioid dependenceImmunodeficiency virusZDV concentrationsControl subjectsMethadone maintenanceDrug usersPharmacotherapyZidovudineBuprenorphineNaltrexoneSignificant differencesLAAMToxicitySubjects